Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALaCART: Immunophenotype-Adapted CAR T-Cell Therapy in B-ALL
NCT05038696Phase 1Recruiting
- Sponsor
- National University Hospital
- Start
- Apr 2021
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in B cell acute lymphoblastic leukemia (B-ALL), sponsored by National University Hospital. Primary endpoint: Proportion of participant who are flow cytometry minimal residual disease (MRD) negative at 30 days. Started Apr 2021; status: recruiting.
02
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05038696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038696.